How do you manage atopic dermatitis in patients who have failed dupilumab?   

The therapeutic landscape for atopic dermatitis is being updated every year, meaning that this question will have different answers in the next few years. In fact, new guidelines are being updated more frequently to capture new drug approvals. As always, medication selection should weigh risks and ...

I like the idea of Nemluvio, because there is good data on effectiveness, there is little risk of serious side effects, dosing is q 4 weeks and can move to q 8 weeks and lower dose, there is no monitoring required, and med is given SC.